Filing Flows › Guardant Health (GH) › Q3 2026
Guardant Health (GH) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Guardant Health (GH) reported revenue of $361M for the third quarter 2026 (Q3 2026), +36% from a year earlier and +8% from the quarter before. Operating margin was -36.8%, net loss $124M (34.5% of revenue).
Guardant Health, Q3 2026: revenue $361M (+36% year over year), operating margin -36.8%, net loss $124M, operating cash flow −$23.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $361M | +8% | +36% |
| Operating profit | −$133M | — | — |
| Net earnings | −$124M | — | — |
| Operating cash flow | −$23.7M | — | — |
What changed
Revenue was $361.0M in Q3 2026, up 36% year over year and up 8% from the previous quarter. Oncology was the largest line at 64% of revenue. Oncology added $46.9M year over year (up 25%), 49% of the total change.
Operating costs exceeded revenue by $132.8M, an operating margin of -36.8%. Total costs grew 36% against revenue growth of 36%. The fastest-growing cost line was General & admin (+71%). The quarter ended with a net loss of $124.4M, wider than the previous quarter's $120.1M loss.
Operating cash flow was −$23.7M. Non-cash charges added back $10.2M of depreciation and amortization and $62.4M of share-based compensation. Working capital and other items added $28.0M. Capital expenditures of $13.5M exceeded it, leaving free cash flow of −$37.2M.
Questions
What was Guardant Health's revenue in the third quarter 2026?
Guardant Health (GH) reported revenue of $361M for the third quarter 2026 (Q3 2026), +36% from a year earlier and +8% from the quarter before.
Was Guardant Health profitable in the third quarter 2026?
Operating loss was $133M (-36.8% of revenue) and net loss $124M.
Source: Guardant Health 10-Q on SEC EDGAR.